Defence Therapeutics Inc. (OTCMKTS:DTCFF) Sees Significant Drop in Short Interest

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 2,900 shares, a decline of 29.3% from the January 31st total of 4,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 0.7 days.

Defence Therapeutics Stock Performance

Shares of Defence Therapeutics stock remained flat at $0.79 during trading on Tuesday. The company’s 50-day moving average is $0.63 and its 200-day moving average is $0.50. Defence Therapeutics has a 52-week low of $0.27 and a 52-week high of $1.32.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.